Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
$78.55
+0.5%
$73.01
$67.37
$130.14
$13.59B1.251.40 million shs562,942 shs
BXP, Inc. stock logo
BXP
BXP
$68.53
-2.2%
$68.98
$54.22
$90.11
$10.86B1.151.34 million shs477,530 shs
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
$28.09
-2.2%
$29.03
$24.02
$32.55
$4.72B1.331.35 million shs318,801 shs
Moderna, Inc. stock logo
MRNA
Moderna
$32.07
+0.0%
$27.62
$23.15
$126.42
$12.41B1.848.88 million shs2.85 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
+0.91%+1.30%+7.55%+0.44%-38.80%
BXP, Inc. stock logo
BXP
BXP
+0.12%+1.42%-3.75%+9.72%+1.02%
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
-0.13%-0.60%-5.36%+7.06%+14.46%
Moderna, Inc. stock logo
MRNA
Moderna
+1.52%-2.23%+23.31%+29.72%-74.38%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
4.396 of 5 stars
3.12.04.22.22.61.71.3
BXP, Inc. stock logo
BXP
BXP
3.7223 of 5 stars
3.21.02.51.82.41.70.6
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
4.2104 of 5 stars
2.34.02.52.82.71.71.3
Moderna, Inc. stock logo
MRNA
Moderna
4.4326 of 5 stars
4.01.00.04.63.22.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
2.17
Hold$99.5426.72% Upside
BXP, Inc. stock logo
BXP
BXP
2.43
Hold$78.0713.93% Upside
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
2.60
Moderate Buy$32.5015.72% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$46.6145.34% Upside

Current Analyst Ratings Breakdown

Latest ARE, MRNA, BXP, and CUZ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/16/2025
BXP, Inc. stock logo
BXP
BXP
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$62.00 ➝ $65.00
7/14/2025
BXP, Inc. stock logo
BXP
BXP
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$86.00 ➝ $82.00
7/14/2025
BXP, Inc. stock logo
BXP
BXP
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$83.00 ➝ $81.00
7/14/2025
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$30.00 ➝ $31.00
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold ➝ Hold
7/2/2025
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$31.00
6/23/2025
BXP, Inc. stock logo
BXP
BXP
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$85.00 ➝ $86.00
6/23/2025
BXP, Inc. stock logo
BXP
BXP
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Neutral$72.00 ➝ $78.00
6/12/2025
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$129.00 ➝ $102.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
$3.12B4.36$8.56 per share9.18$129.29 per share0.61
BXP, Inc. stock logo
BXP
BXP
$3.41B3.18$7.49 per share9.15$50.21 per share1.36
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
$897.85M5.25$2.42 per share11.61$29.05 per share0.97
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.83N/AN/A$28.33 per share1.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
$322.95M$0.76103.408.176.524.62%0.64%0.38%7/21/2025 (Estimated)
BXP, Inc. stock logo
BXP
BXP
$14.27M-$0.02N/A9.435.72-0.16%3.72%1.16%7/29/2025 (Estimated)
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
$45.96M$0.3385.219.892.685.97%1.15%0.65%7/31/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$8.73N/AN/AN/A-105.67%-28.69%-21.94%7/30/2025 (Estimated)

Latest ARE, MRNA, BXP, and CUZ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.97N/AN/AN/A$116.26 millionN/A
7/31/2025Q2 2025
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
$0.70N/AN/AN/A$243.73 millionN/A
7/29/2025Q2 2025
BXP, Inc. stock logo
BXP
BXP
$1.67N/AN/AN/A$845.09 millionN/A
7/21/2025Q2 2025
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
$2.30N/AN/AN/A$748.02 millionN/A
5/1/2025Q1 2025
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
$0.71$0.74+$0.03$0.74$238.49 million$6.81 million
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.92-$2.52+$0.40-$2.52$130.35 million$108.00 million
4/29/2025Q1 2025
BXP, Inc. stock logo
BXP
BXP
$1.65$1.64-$0.01$1.64$833.89 million$865.22 million
4/28/2025Q1 2025
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
$2.28$2.30+$0.02$1.65$755.64 million$758.16 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
$5.286.72%N/A694.74%15 Years
BXP, Inc. stock logo
BXP
BXP
$3.925.72%N/AN/A N/A
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
$1.284.56%N/A387.88%N/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest ARE, MRNA, BXP, and CUZ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/20/2025
BXP, Inc. stock logo
BXP
BXP
quarterly$0.985.47%6/30/20256/30/20257/31/2025
6/18/2025
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
quarterly$0.324.2%7/7/20257/7/20257/17/2025
6/2/2025
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
quarterly$1.327.64%6/30/20256/30/20257/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
0.60
0.22
0.22
BXP, Inc. stock logo
BXP
BXP
2.04
4.23
4.23
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
0.62
0.89
0.89
Moderna, Inc. stock logo
MRNA
Moderna
N/A
4.22
4.14

Institutional Ownership

CompanyInstitutional Ownership
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
96.54%
BXP, Inc. stock logo
BXP
BXP
98.72%
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
94.38%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
1.08%
BXP, Inc. stock logo
BXP
BXP
1.49%
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
1.40%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
590172.99 million171.12 millionOptionable
BXP, Inc. stock logo
BXP
BXP
780158.32 million155.97 millionOptionable
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
290167.91 million165.56 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800386.74 million344.20 millionOptionable

Recent News About These Companies

William Blair Estimates Moderna's Q2 Earnings (NASDAQ:MRNA)
Eye on Patents: Taking mRNA vaccines beyond COVID-19
William Blair Issues Negative Outlook for Moderna Earnings
Cwm LLC Buys 28,831 Shares of Moderna, Inc. (NASDAQ:MRNA)
Moderna patent for mRNA vaccine knocked back, for now
Why Moderna (MRNA) Stock Is Falling Today
Moderna: Ready For The Redemption Arc
Victoria funds mRNA breakthrough research
Moderna (NasdaqGS:MRNA) Added to Russell Midcap Indexes

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alexandria Real Estate Equities stock logo

Alexandria Real Estate Equities NYSE:ARE

$78.55 +0.40 (+0.51%)
As of 12:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche since our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative life science, agtech, and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a total market capitalization of $33.1 billion and an asset base in North America of 73.5 million SF as of December 31, 2023, which includes 42.0 million RSF of operating properties, 5.5 million RSF of Class A/A+ properties undergoing construction and one near-term project expected to commence construction in the next two years, 2.1 million RSF of priority anticipated development and redevelopment projects, and 23.9 million SF of future development projects. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in life science, agtech, and advanced technology mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science, agrifoodtech, climate innovation, and technology companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

BXP stock logo

BXP NYSE:BXP

$68.53 -1.57 (-2.24%)
As of 12:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Boston Properties, Inc. (NYSE: BXP) (BXP or the Company) is the largest publicly traded developer, owner, and manager of premier workplaces in the United States, concentrated in six dynamic gateway markets - Boston, Los Angeles, New York, San Francisco, Seattle, and Washington, DC. BXP has delivered places that power progress for our clients and communities for more than 50 years. BXP is a fully integrated real estate company, organized as a real estate investment trust (REIT). Including properties owned by joint ventures, BXP's portfolio totals 53.3 million square feet and 188 properties, including 10 properties under construction/redevelopment. BXP's properties include 167 office properties, 14 retail properties (including two retail properties under construction/redevelopment), six residential properties (including one residential property under construction) and one hotel. BXP is well-known for its inhouse building management expertise and responsiveness to clients' needs. BXP holds a superior track record of developing premium Central Business District (CBD) office buildings, successful mixed-use complexes, suburban office centers and build-to-suit projects for a diverse array of creditworthy clients. BXP actively works to promote its growth and operations in a sustainable and responsible manner. BXP has earned a twelfth consecutive GRESB Green Star recognition and the highest GRESB 5-star Rating. BXP, an S&P 500 company, was founded in 1970 by Mortimer B. Zuckerman and Edward H. Linde and became a public company in 1997.

Cousins Properties stock logo

Cousins Properties NYSE:CUZ

$28.08 -0.64 (-2.21%)
As of 12:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cousins Properties Incorporated ("Cousins") is a fully integrated, self-administered, and self-managed real estate investment trust (REIT). The Company, based in Atlanta and acting through its operating partnership, Cousins Properties LP, primarily invests in Class A office buildings located in high-growth Sun Belt markets. Founded in 1958, Cousins creates shareholder value through its extensive expertise in the development, acquisition, leasing, and management of high-quality real estate assets. The Company has a comprehensive strategy in place based on a simple platform, trophy assets, and opportunistic investments.

Moderna stock logo

Moderna NASDAQ:MRNA

$32.07 +0.01 (+0.03%)
As of 12:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.